MAB1061
Anti-Bone Sialoprotein II Antibody, CT, clone ID1.2
clone ID1.2, Chemicon®, from mouse
别名:
BSPII, Integrin-binding Sialoprotein
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
ID1.2, monoclonal
Application:
ELISA
immunocytochemistry
immunohistochemistry
radioimmunoassay
western blot
immunocytochemistry
immunohistochemistry
radioimmunoassay
western blot
Species reactivity:
human
Citations:
4
Technique(s):
ELISA: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable (paraffin)
radioimmunoassay: suitable
western blot: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable (paraffin)
radioimmunoassay: suitable
western blot: suitable
Uniprot accession no.:
产品名称
Anti-Bone Sialoprotein II Antibody, CT, clone ID1.2, clone ID1.2, Chemicon®, from mouse
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
ID1.2, monoclonal
species reactivity
human
should not react with
bovine, rat, pig
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable (paraffin)
radioimmunoassay: suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... IBSP(3381)
pig ... Ibsp(397137)
rat ... Ibsp(24477)
Application
Research Category
Cell Structure
Cell Structure
Research Sub Category
Osteobiology
Osteobiology
This Anti-Bone Sialoprotein II Antibody, C-terminus, clone ID1.2 is validated for use in ELISA, RIA, WB, IC, IH(P) for the detection of Bone Sialoprotein II.
Western blot: (1μg/mL)
Immunohistochemistry on paraffin embedded tissue sections: (1μg/mL)
Immunocytochemistry: (1:100)
ELISA: (1μg/mL)
RIA
Optimal working dilutions must be determined by the end user.
Immunohistochemistry on paraffin embedded tissue sections: (1μg/mL)
Immunocytochemistry: (1:100)
ELISA: (1μg/mL)
RIA
Optimal working dilutions must be determined by the end user.
Biochem/physiol Actions
Recombinant and native human bone sialoprotein II (BSPII). Does not react with osteopontin (BSPI) or osteonectin.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
Bone Sialoprotein II is one of the major noncollagenous proteins in the extracellular matrix of bone. It is a phosphorylated glycoprotein with an approximate molecular weight of 70 kDa. The protein has been found in osteoblasts and osteocytes. Diseases concerning bone turnover, pathological bone alterations, as well as the rapid increase of osteoporosis make it necessary to establish new markers. Bone Sialoprotein is discussed as a potential serum marker for monitoring bone remodeling.
Immunogen
Bone Sialoprotein isolated from human bones.
Epitope: C-terminus
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Replaces: AB1855
Physical form
Format: Purified
Purified immunoglobulin from culture supernatant. Lyophilized from 50 mM TRIS, pH7.4.
Preparation Note
Maintain lyophilized material at 2-8°C. Reconstitute with 100μL sterile distilled water and store at -20°C in undiluted aliquots up to 12 months. Avoid repeated freeze/thaw cycles.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
10 - Combustible liquids
wgk
WGK 1
Xiaonan Xin et al.
Stem cells translational medicine, 3(10), 1125-1137 (2014-08-15)
The use of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) for study and treatment of bone diseases or traumatic bone injuries requires efficient protocols to differentiate hESCs/iPSCs into cells with osteogenic potential and the ability to
Strategies for accelerating osteogenesis through nanoparticle-based DNA/mitochondrial damage repair.
Hye Jin Kim et al.
Theranostics, 12(14), 6409-6421 (2022-09-29)
The efficiency of gene therapy is often dictated by the gene delivery system. Cationic polymers are essential elements of gene delivery systems. The relatively cheap cationic polymer, polyethyleneimine, has high gene delivery efficiency and is often used for gene delivery.
Liisa T Kuhn et al.
Tissue engineering. Part A, 20(1-2), 365-377 (2013-08-21)
The in vivo osteogenesis potential of mesenchymal-like cells derived from human embryonic stem cells (hESC-MCs) was evaluated in vivo by implantation on collagen/hydroxyapatite scaffolds into calvarial defects in immunodeficient mice. This study is novel because no osteogenic or chondrogenic differentiation
Xiaonan Xin et al.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 67(6), 401-417 (2019-03-09)
The effectiveness of autologous cell-based skeletal repair continues to be controversial in part because in vitro predictors of in vivo human bone formation by cultured human progenitor cells are not reliable. To assist in the development of in vivo assays
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持